Biotalys N.V (BTLS) | Financial Analysis & Statements
Biotalys N.V. Small-cap Basic Materials
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2021Income Metrics
Revenue
0
Operating Income
-4.4M
Net Income
-3.5M
Balance Sheet Metrics
Total Assets
29.0M
Total Liabilities
9.2M
Shareholders Equity
19.8M
Debt to Equity
0.46
Cash Flow Metrics
Operating Cash Flow
-4.1M
Free Cash Flow
-2.4M
Revenue & Profitability Trend
Biotalys N.V Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 11.0M | 16.6M | 18.8M | 13.9M | 11.5M |
| Selling, General & Administrative | 5.7M | 6.9M | 6.7M | 6.2M | 3.2M |
| Other Operating Expenses | -1.4M | -1.5M | -1.5M | -981.0K | -930.0K |
| Total Operating Expenses | 15.2M | 22.0M | 23.9M | 19.1M | 13.7M |
| Operating Income | -13.5M | -20.9M | -22.5M | -18.1M | -13.3M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 534.0K | 655.0K | 23.0K | 5.0K | 1.0K |
| Interest Expense | 157.0K | 161.0K | 247.0K | 246.0K | 86.0K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -13.1M | -20.5M | -22.8M | -16.9M | -10.7M |
| Income Tax | 40.0K | 56.0K | -38.0K | 16.0K | 13.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -13.2M | -20.5M | -22.7M | -16.9M | -10.8M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -11.2M | -18.5M | -20.9M | -16.5M | -12.3M |
| EPS (Basic) | €-0.40 | €-0.65 | €-0.74 | €-1.10 | €-0.36 |
| EPS (Diluted) | €-0.40 | €-0.65 | €-0.74 | €-1.10 | €-0.36 |
| Basic Shares Outstanding | 33254585 | 31587240 | 30898175 | 15427189 | 30020387 |
| Diluted Shares Outstanding | 33254585 | 31587240 | 30898175 | 15427189 | 30020387 |
Income Statement Trend
Biotalys N.V Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 22.6M | 21.6M | 34.1M | 56.1M | 23.1M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 522.0K | 490.0K | 746.0K | 279.0K | 76.0K |
| Total Current Assets | 26.2M | 24.9M | 37.8M | 58.9M | 25.5M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 7.0M | 7.0M | 6.1M | 5.6M | 4.7M |
| Goodwill | 574.0K | 642.0K | 597.0K | 665.0K | 791.0K |
| Intangible Assets | 574.0K | 642.0K | 597.0K | 665.0K | 791.0K |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 157.0K | 3.0K | 2.0K | - | 30.0K |
| Total Non-Current Assets | 10.5M | 11.7M | 11.8M | 11.3M | 10.8M |
| Total Assets | 36.7M | 36.6M | 49.5M | 70.3M | 36.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 1.2M | 1.3M | 2.7M | 1.9M | 2.5M |
| Short-term Debt | 1.2M | 1.2M | 1.2M | 1.2M | 888.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.0K | 1.0K | 2.0K | 1.0K | - |
| Total Current Liabilities | 4.8M | 5.5M | 6.0M | 5.2M | 6.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 3.7M | 4.8M | 5.3M | 6.0M | 4.3M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | -1.0K | - | - | - | - |
| Total Non-Current Liabilities | 4.4M | 5.5M | 5.4M | 6.2M | 4.5M |
| Total Liabilities | 9.1M | 11.0M | 11.4M | 11.4M | 10.6M |
| Equity | |||||
| Common Stock | 5.5M | 46.2M | 44.5M | 82.0M | 62.8M |
| Retained Earnings | -11.7M | -40.2M | -19.7M | -55.9M | -34.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 27.6M | 25.6M | 38.1M | 58.9M | 25.6M |
| Key Metrics | |||||
| Total Debt | 4.8M | 6.1M | 6.5M | 7.2M | 5.2M |
| Working Capital | 21.5M | 19.4M | 31.8M | 53.7M | 19.4M |
Balance Sheet Composition
Biotalys N.V Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -13.5M | -20.9M | -22.5M | -18.1M | -13.3M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 658.0K | 1.0M | 1.7M | 511.0K | 550.0K |
| Working Capital Changes | -968.0K | 2.0M | -1.0M | -144.0K | 875.0K |
| Operating Cash Flow | -13.8M | -17.7M | -21.8M | -17.7M | -11.8M |
| Investing Activities | |||||
| Capital Expenditures | -107.0K | -312.0K | -707.0K | -1.3M | -3.8M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -10.0K | 0 | 0 | 0 | -2.1M |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -118.0K | -311.0K | -707.0K | -1.3M | -5.9M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | 0 | 2.8M | 1.2M |
| Debt Repayment | -1.3M | -1.3M | -1.2M | -1.1M | -1.0M |
| Financing Cash Flow | 13.3M | 5.7M | -997.0K | 51.3M | 15.3M |
| Free Cash Flow | -12.8M | -18.7M | -20.8M | -18.1M | -13.5M |
| Net Change in Cash | -584.0K | -12.4M | -23.5M | 32.3M | -2.4M |
Cash Flow Trend
Biotalys N.V Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-5.82
Forward P/E
-13.12
Price to Book
4.40
Price to Sales
-1,199.11
PEG Ratio
-13.12
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-589.49%
Return on Equity
-75.33%
Return on Assets
-32.17%
Financial Health
Current Ratio
3.61
Debt to Equity
21.67
Beta
1.01
Per Share Data
EPS (TTM)
€-0.42
Book Value per Share
€0.53
Revenue per Share
€0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| BTLS | 87.5M | -5.82 | 4.40 | -75.33% | 0.00% | 21.67 |
| Tessenderlo Group NV | 1.3B | 37.21 | 0.74 | -4.43% | -2.94% | 11.70 |
| Syneos Health | 5.7B | 377.86 | 0.94 | -1.25% | -1.04% | 48.61 |
| Titan Cement | 3.5B | 14.74 | 1.77 | 13.18% | 8.85% | 33.45 |
| Solvay SA | 2.9B | 99.64 | 2.86 | 2.98% | 0.63% | 200.56 |
| Azelis Group NV | 2.5B | 22.61 | 0.94 | 4.03% | 2.71% | 69.00 |
Financial data is updated regularly. All figures are in the company's reporting currency.